Century Therapeutics
Century Therapeutics is a biotechnology company developing allogeneic, iPSC-derived cell therapies for autoimmune diseases and cancer.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Century Therapeutics is an innovative biotechnology company building an industry-leading, allogeneic, iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases, including type 1 diabetes, and cancer. The company is headquartered in Philadelphia, United States, and is publicly traded on NASDAQ under the ticker IPSC.
History
Century Therapeutics is a biotechnology company based in Philadelphia, United States. It is developing allogeneic, iPSC-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. The company is publicly traded on NASDAQ under the ticker IPSC.
Recent events
- Unconfirmed
Century Therapeutics acquires Empirica Therapeutics[4]
Reported:
Empirica Therapeutics was acquired by Century Therapeutics. The acquired business is now known as Century Therapeutics Canada, and Century will further develop Empirica's proof-of-principle glioblastoma treatment.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/century-therapeutics · Editorial policy · How profiles are compiled